Beryl Drugs Ltd Upgraded to Hold as Technicals Improve and Valuation Attracts

Technical Trends Shift to Mildly Bullish

The primary catalyst for the upgrade stems from a notable improvement in the company’s technical grade. The technical trend has shifted from mildly bearish to mildly bullish, signalling a more favourable near-term outlook for the stock price. Key technical indicators present a mixed but overall positive picture. On a weekly basis, the Moving Average Convergence Divergence (MACD) is bullish, supported by bullish Bollinger Bands and a positive Know Sure Thing (KST) indicator. Conversely, monthly MACD remains bearish, though monthly Bollinger Bands and KST have turned mildly bullish, suggesting emerging momentum.

Relative Strength Index (RSI) readings on both weekly and monthly charts show no clear signals, indicating the stock is not currently overbought or oversold. Daily moving averages remain mildly bearish, reflecting some short-term caution. The Dow Theory does not indicate a definitive trend on either weekly or monthly timeframes. Overall, the technical picture has improved sufficiently to warrant a more optimistic stance, with the stock price rising 5.27% on the day to ₹23.96, approaching its 52-week high of ₹30.00.

Valuation Appears Very Attractive

Beryl Drugs is currently trading at a discount relative to its peers’ historical valuations, which has contributed to the upgrade. The company’s Return on Capital Employed (ROCE) stands at 7.6%, a figure that, while modest, supports a valuation that is considered very attractive. The Enterprise Value to Capital Employed ratio is a low 1.2, indicating the stock is undervalued compared to the capital it employs to generate earnings. This valuation appeal is particularly relevant given the company’s micro-cap status, where market inefficiencies often create opportunities for investors.

Despite a 16% decline in profits over the past year, the stock has delivered a 6.30% return over the same period, outperforming the Sensex which fell by 8.61%. Over longer horizons, Beryl Drugs has significantly outperformed the benchmark, with a five-year return of 157.36% compared to Sensex’s 45.53%, underscoring its potential for capital appreciation.

Financial Trend Shows Positive Quarterly Performance

Financially, Beryl Drugs has demonstrated encouraging signs in the most recent quarter (Q4 FY25-26). The company reported its highest-ever quarterly PBDIT of ₹1.34 crore, PBT excluding other income at ₹0.87 crore, and PAT at ₹0.56 crore. These figures mark a positive inflection point after a period of subdued profitability. However, the longer-term financial trend remains mixed. While net sales have grown at a modest annual rate of 6.22% over the past five years and operating profit at 9.30%, the company’s ability to service debt is weak, with an average EBIT to interest ratio of just 0.94.

Return on Capital Employed averaged 8.19% over the long term, indicating only average efficiency in generating returns from capital invested. The recent quarterly improvements, however, suggest potential for a turnaround in financial momentum, justifying a more cautious Hold rating rather than a Sell.

Promoter Confidence Strengthens

Another positive development supporting the upgrade is the rising promoter confidence. Promoters have increased their stake by 1.1% over the previous quarter, now holding 27.48% of the company’s equity. This increase signals strong insider belief in the company’s future prospects and often acts as a stabilising factor for the stock price. Such insider buying is typically viewed favourably by investors as it aligns management’s interests with those of shareholders.

Stock Performance Relative to Sensex

Examining Beryl Drugs’ returns relative to the Sensex reveals a nuanced picture. Over the past week, the stock gained 3.99% while the Sensex declined 0.54%, reflecting short-term outperformance. Over one month, however, the stock fell 1.52% against a 4.05% rise in the Sensex, indicating some volatility. Year-to-date, Beryl Drugs has returned 2.39%, outperforming the Sensex’s negative 10.23%. Over one year, the stock’s 6.30% gain contrasts with the Sensex’s 8.61% loss, and over three and five years, the stock has significantly outpaced the benchmark. The 10-year return is negative at -33.07%, lagging the Sensex’s strong 182.02% gain, highlighting the company’s challenges over the longer term.

Balancing Strengths and Weaknesses

While the upgrade to Hold reflects several positive developments, it is important to recognise the company’s ongoing challenges. The long-term fundamental strength remains weak, with average ROCE below 10% and modest growth rates in sales and operating profit. The company’s debt servicing capacity is also a concern, with an EBIT to interest ratio below 1, indicating potential vulnerability to interest rate fluctuations or economic downturns.

Technically, although the trend has improved, some indicators remain mixed or mildly bearish on shorter timeframes. Valuation is attractive but must be weighed against the company’s micro-cap status and inherent liquidity risks. Investors should therefore approach Beryl Drugs with measured optimism, considering it a potential turnaround candidate rather than a definitive growth stock at this stage.

Conclusion: A Cautious Hold with Upside Potential

The upgrade of Beryl Drugs Ltd from Sell to Hold by MarketsMOJO on 8 July 2026 is driven by improved technical signals, attractive valuation metrics, positive quarterly financial results, and increased promoter confidence. These factors collectively suggest the stock is stabilising and may be poised for moderate gains. However, the company’s weak long-term fundamentals and debt servicing concerns temper enthusiasm, making Hold the appropriate rating for now.

Investors should monitor upcoming quarterly results and technical developments closely to assess whether the company can sustain its recent improvements and translate them into stronger long-term growth. For those seeking exposure to the Pharmaceuticals & Biotechnology sector, Beryl Drugs offers a micro-cap opportunity with potential upside balanced by risks inherent in smaller companies.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today